These results indicate that Me3-NFAT5 K668 is a master regulator of tumor progression and TMZ response, targeting NFAT5 K668 methylation as an effective therapeutic strategy to improve TMZ response in GBM. This evidence concerns the gene NFAT5 and glioblastoma.